347 related articles for article (PubMed ID: 33230180)
1. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
[TBL] [Abstract][Full Text] [Related]
2. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
3. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
4. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of drug bank compounds against 3C-like protease (3CL
Joshi T; Sharma P; Mathpal S; Joshi T; Maiti P; Nand M; Pande V; Chandra S
Mol Divers; 2022 Aug; 26(4):2243-2256. PubMed ID: 34637068
[TBL] [Abstract][Full Text] [Related]
6. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
7. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
[TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
9. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel inhibitors of SARS-CoV-2 main protease (M
Verma S; Patel CN; Chandra M
J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
[TBL] [Abstract][Full Text] [Related]
13. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
14. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
15. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
Elzupir AO
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
17. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
19. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
20. Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations.
Zrieq R; Ahmad I; Snoussi M; Noumi E; Iriti M; Algahtani FD; Patel H; Saeed M; Tasleem M; Sulaiman S; Aouadi K; Kadri A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
